Trial Profile

Phase I trial of IMO 9200 in volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMO 9200 (Primary)
Indications Autoimmune disorders
Focus Adverse reactions
Sponsors Aceragen; Idera Pharmaceuticals

Most Recent Events

18 May 2015 Results published in the Idera Pharmaceuticals Media Release.
18 May 2015 Status changed from recruiting to completed, according to an Idera Pharmaceuticals media release.
07 Nov 2014 Idera Pharmaceuticals expects to select a lead autoimmune disease indication for further development of IMO-9200 in the first half of 2015, according to a media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com